Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: A new framework for design and reporting

Pain

Volumn 156, Issue 8, 2015, Pages 1382-1395

  Moore, R Andrew ^a   Wiffen, Philip J ^a   Eccleston, Christopher ^b   Derry, Sheena ^a   Baron, Ralf ^c   Bell, Rae F ^d   Furlan, Andrea D ^e   Gilron, Ian ^f   Haroutounian, Simon ^g   Katz, Nathaniel P ^h   Lipman, Arthur G ⁱ   Morley, Stephen ^j   Peloso, Paul M ^k   Quessy, Steve N ^l   Seers, Kate ^m   Strassels, Scott A ^h   Straube, Sebastian ⁿ  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Bath   (United Kingdom)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e INSTITUTE FOR WORK AND HEALTH   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Analgesic Solutions ^*  (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k ABBVIE INC   (United States)

^l qd Consulting LLC   (United States)

^m UNIVERSITY OF WARWICK   (United Kingdom)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

Enriched enrolment; Methods; Randomised withdrawal; Recommendations; Systematic review

Indexed keywords

ANALGESIC AGENT; PLACEBO;

ADVERSE OUTCOME; CHRONIC PAIN; CLINICAL DECISION MAKING; DOSE RESPONSE; DRUG DOSE TITRATION; ENRICHED ENROLMENT RANDOMIZED WITHDRAWAL; FUTUROLOGY; HUMAN; INFORMATION PROCESSING; MEDLINE; METHODOLOGY; NOTE; PAIN INTENSITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SAMPLE SIZE; STUDY DESIGN; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNCERTAINTY; PROCEDURES; RISK FACTOR; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTOR;

ANALGESICS; CHRONIC PAIN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; UNCERTAINTY;

EID: 84945257651     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000088     Document Type: Note

References (88)

1. Amery W, Dony J. A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol 1975;15:674-9.
2. AUREF. PaPaS author and referee guidance. Available at: http://papas. cochrane. org/papas-documents. Accessed December 15, 2014.
3. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11:999-1005.
4. Baron R, Freynhagen R, Tölle TR, Cloutier C, Leon T, Murphy TK, Phillips K; A0081007 Investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. PAIN 2010;150:420-7.
5. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408.
6. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage enriched enrollment design. PAIN 1995;60:267-74.
7. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, Lacouture PG. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9.
8. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/ MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83:559-66.
9. Christakis NA. Does this drug work for you? BMJ 2008;337:a2281.
10. Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Esdaile JM. Randomized, double-blind, placebocontrolled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004;51:738-45.
11. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. Final Draft. 2011. Available at: http://www. ema. europa. eu/docs/en-GB/document-library/Scientific-guideline/2011/ 12/WC500119785. pdf. Accessed December 15, 2014.
12. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
13. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, Sharma U. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebocontrolled trial with pregabalin. PAIN 2008;136:419-31.
14. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 2014;7:CD010958.
15. Dworkin RH, McDermott MP, Farrar JT, O'Connort AB, Senn S. Interpreting patient treatment response in analgesic clinical trials: implications for genotyping, phenotyping, and personalized pain treatment. PAIN 2014;155:457-60.
16. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
17. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. PAIN 2001;94:149-58.
18. Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extendedrelease oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 2011;7:193-202.
19. Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag 2011;16:337-51.
20. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves post herpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. PAIN 1999;80: 533-8.
21. Ghimire S, Kyung E, Kang W, Kim E. Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact generalmedical journals. Trials 2012;13:77.
22. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain 2011;27:185-93.
23. Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin 2010;26:1505-18.
24. Hale ME, Ahdieh H, Ma T, Rauck R; Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84.
25. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic lowback pain: results of a randomized, doubleblind, placebo-and active-controlled phase III study. J Pain 2005;6:21-8.
26. Hale ME, Nalamachu SR, Khan A, Kutch M. Effectiveness and gastrointestinal tolerability during conversion and titration with oncedaily OROS hydromorphone extended release in opioid-tolerant patients with chronic low back pain. J Pain Res 2013;6:319-29.
27. Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, Michelson D, Bolognese J, Alon A, Rosenberg E, Herman G, Wang H. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. PAIN 2011;152:514-21.
28. Kalliomäki J, Miller F, Ka gedal M, Karlsten R. Early phase drug development for treatment of chronic pain-options for clinical trial and program design. Contemp Clin Trials 2012;33:689-99.
29. Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain 2009;25:797-807.
30. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010;122:112-28.
31. Katz N, Rauck R, Ahdieh H, Ma T, Gerritsen van der Hoop R, Kerwin R, Podolsky G. A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patientswith chronic low back pain. Curr Med Res Opin 2007;23:117-28.
32. Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA. Costeffectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med 2014;160:221-32.
33. Kellogg KM, Markman J. Enrichment designs. In: Ravina B, Cummings J, McDermott MP, Poole RM, editors. Clinical trials in neurology. Cambridge: Cambridge University Press, 2012. P. 127-134.
34. Kongsgaard UE, Poulain P. Transdermal fentanyl for pain control in adults with chronic cancer pain. Eur J Pain 1998;2:53-62.
35. Kopec JA, Abrahamowicz M, Esdaile JM. Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol 1993;46:959-71.
36. Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Clin Ther 2007;29:2179-93.
37. Landau R. One size does not fit all: genetic variability of mu-opioid receptor and postoperative morphine consumption. Anesthesiology 2006;105:235-7.
38. Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, Etropolski M. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99.
39. Leber PD, Davis CS. Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 1998;19: 178-87.
40. Lemeshow AR, Blum RE, Berlin JA, Stoto MA, Colditz GA. Searching one or two databases was insufficient for meta-analysis of observational studies. J Clin Epidemiol 2005;58:867-73.
41. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367: 1355-60.
42. Lötsch J. Genetic variability of pain perception and treatment-clinical pharmacological implications. Eur J Clin Pharmacol 2011;67:541-51.
43. Lötsch J, Doehring A, Mogil JS, Arndt T, Geisslinger G, Ultsch A. Functional genomics of pain in analgesic drug development and therapy. Pharmacol Ther 2013;139:60-70.
44. Lund K, Vase L, Petersen GL, Jensen TS, Finnerup NB. Randomised controlled trials may underestimate drug effects: balanced placebo trial design. PLoS One 2014;9:e84104.
45. Lynch ME, Clark AJ, Sawynok J. Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrolment design. PAIN 2003;103:111-7.
46. Maier C, Baron R. Physicians do not treat averages-but therapy responders! [in German]. Schmerz 2012;26:5-7.
47. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011;11:163-9.
48. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. PAIN 2008;135:217-20.
49. McQuay HJ, Poon KH, Derry S, Moore RA. Acute pain: combination treatments and how we measure their efficacy. Br J Anaesth 2008;101: 69-76.
50. Moore A, Straube S, Derry S, McQuay H. Does this work for you? Individuals, averages, and evidence based medicine. BMJ 2008;337: a2585.
51. Moore RA. What works for whom? Determining the efficacy and harm of treatments for pain. PAIN 2013;154(suppl 1):S77-86.
52. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions-individual patient data responder analysis. Eur J Pain 2014; 18:67-75.
53. Moore RA, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690.
54. Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 2005;5:18.
55. Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, Bell RF, Kalso E, Rowbotham MC; ACTINPAIN writing group of the IASP Special Interest Group (SIG) on Systematic Reviews in Pain Relief. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. PAIN 2010;149:173-76.
56. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract 2014;14:79-94.
57. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, McQuay H; ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief; Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors. Evidence in chronic pain-establishing best practice in the reporting. PAIN 2010; 150:386-89.
58. Moore RA, Gavaghan D, Trame r MR, Collins SL, McQuay HJ. Size is everything-large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. PAIN 1998;78:209-16.
59. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a metaanalysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis 2010;69:374-9.
60. Moore RA, Straube S, Aldington D. Pain measures and cut-offs-'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013; 68:400-12.
61. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, Bell RF, Hamunen K, Phillips C, McQuay H. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. PAIN 2012;153:265-8.
62. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; CD007076.
63. Morris J, Gardner M. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner M, Altman D, editors. Statistics with confidence-confidence intervals and statistical guidelines. London: British Medical Journal, 1995. P. 50-63.
64. National Institute for Health and Clinical Excellence. Neuropathic pain-pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings. London: National Institute for Health and Care Excellence, 2013. Available from: http://www. nice. org. uk/nicemedia/live/13566/64189/64189. pdf. Accessed December 15, 2014.
65. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebocontrolled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving longterm Sativex (nabiximols). Mult Scler 2012;18:219-28.
66. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther 2012;91:550-4.
67. Quessy SN. Two-stage enriched enrolment pain trials: a brief review of designs and opportunities for broader application. PAIN 2010;148:8-13.
68. Raskin P, Huffman C, Toth C, Asmus MJ, Messig M, Sanchez RJ, Pauer L. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain 2014;30:379-90.
69. Ring HA, Heller AJ, Farr IN, Reynolds EH. Vigabatrin: rational treatment for chronic epilepsy. J Neurol Neurosurg Psychiatry 1990;53:1051-5.
70. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002;20: 4478-84.
71. Rothwell PM. External validity of randomised controlled trials: to whom do the results of this trial apply? Lancet 2005;365:82-93.
72. Rowbotham MC, Gilron I, Glazer C, Rice AS, Smith BH, Stewart WF, Wasan AD. Can pragmatic trials help us better understand chronic pain and improve treatment? PAIN 2013;154:643-6.
73. Ruppen W, Derry S, McQuay H, Moore RA. Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. Anesthesiology 2006;105:394-9.
74. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7.
75. Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol 2000;27:772-8.
76. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967;20:637-48.
77. Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomizedwithdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27: 151-62.
78. Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-nä?ve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2011;42:903-17.
79. Strand V, Kosinski M, Gnanasakthy A, Mallya U, Mpofu S. Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health Qual Life Outcomes 2014;12:31.
80. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol 2008;66:266-75.
81. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia-responder analysis from individual patient data. BMC Musculosklelet Disord 2010;11:150.
82. Temple R. Enrichment of clinical study populations. Clin Pharmacol Ther 2010;88:774-8.
83. Temple RJ. Special study designs: early escape, enrichment, studies in non-responders. Commun Statistics Theory Methods 1994;23:499-531.
84. Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, Garven A, Bestard J, Korngut L. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. PAIN 2012;153:2073-82.
85. Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 2011;8:e1000434.
86. Vink A, Shapiro DY, Karcher K, Rauschkolb C, Lange B, Pennett D, Etropolski MS. Efficacy and tolerability of tapentadol extended release in patients with chronic, painful diabetic peripheral neuropathy: results of a phase 3, randomized-withdrawal, placebo-controlled study. Poster presented: at the 31st annual scientific meeting of the American Pain Society; May 16-19, 2012; Honolulu, Hawaii.
87. Vorsanger GJ, Xiang J, Gana TJ, Pascual ML, Fleming RR. Extendedrelease tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag 2008;4:87-97.
88. Woolf SH. The meaning of translational research and why it matters. JAMA 2008;299:211-3.